Background: Cognitive decline is inadequately captured by the standard neurological
examination. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein …

Background Little is known about the association between the socioeconomic status (SES)
and disability risk of patients with Multiple Sclerosis (MS). Objective The aim of this study …

Background Therapeutic options targeting inflammation in multiple sclerosis (MS) have
evolved rapidly for relapsing–remitting MS, whereas few therapies are available for …

Objective In multiple sclerosis (MS), clinical impairment is likely due to both structural
damage and abnormal brain function. We assessed the added value of integrating structural …

Background PIRA (progression independent of relapse) has emerged as a term to quantify
the proportion of disability worsening due to non-inflammatory neurodegenerative …

Background Patients with multiple sclerosis (MS) who discontinue fingolimod might present
with rebound activity. The reasons for the development of rebound have been identified, but …

Background and purpose There is a lack of evidence guiding discontinuation of disease‐
modifying therapy (DMT) in relapsing multiple sclerosis (RMS). Thus, the objective of this …

Background: Recent progress in multiple sclerosis (MS) management has contributed to a
greater life expectancy in persons with MS. Ageing with MS comes with unique challenges …

The search for the genetic foundation of multiple sclerosis (MS) severity remains elusive. It
is, in fact, controversial whether MS severity is a stable feature that predicts future disability …

Background and Objectives: Determining the clinical course of multiple sclerosis (MS) and
prediction of long-term disability can be a big challenge. To determine early clinical features …